Emerging gonadotropin-releasing hormone agonists

Bibliography

• Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205
   PubMed Web of Science ®Google Scholar
• Stojilkovic SS, Catt KJ. Expression and signal transduction pathways of gonadotropin-releasing hormone receptors. Recent Prog Horm Res 1995;50:161-205
   PubMedGoogle Scholar
• Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405
   PubMed Web of Science ®Google Scholar
• Borroni R, Di Blasio AM, Gaffuri B, Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol 2000;159:37-43
   PubMed Web of Science ®Google Scholar
• Tesone M, Vitale A, Parborell F. Gonadotropin- releasing- hormone action on ovarian steroidgenesis and apoptosis. Res Trends 1999;2:81-91
   Google Scholar
• MacFarlane M, Williams AC. Apoptosis and disease: a life or death decision. EMBO Rep 2004;5:674-8
   PubMed Web of Science ®Google Scholar
• Stouffer RL, Martinez-Chequer JC, Molskness TA, Regulation and action of angiogenic factors in the primate ovary. Arch Med Res 2001;32:567-75
   PubMed Web of Science ®Google Scholar
• Tesone M, Bilotas M, Baranao RI, Meresman G. The role of GnRH analogues in endometriosis-associated apoptosis and angiogenesis. Gynecol Obstet Invest 2008;66:10-18
   PubMed Web of Science ®Google Scholar
• So WK, Cheng JC, Poon SL, Leung PC. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 2008;275:5496-511
   PubMed Web of Science ®Google Scholar
• Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev 2009;(4):CD004562
   Google Scholar
• Millar RP, Lu ZL, Pawson AJ, Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25:235-75
   PubMed Web of Science ®Google Scholar
• Yang-Feng TL, Seeburg PH, Francke U. Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2—p21). Somat Cell Mol Genet 1986;12:95-100
   PubMedGoogle Scholar
• Radovick S, Wondisford FE, Nakayama Y, Isolation and characterization of the human gonadotropin-releasing hormone gene in the hypothalamus and placenta. Mol Endocrinol 1990;4:476-80
   PubMed Web of Science ®Google Scholar
• Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005;26:283-306
   PubMed Web of Science ®Google Scholar
• White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998;95:305-9
   PubMed Web of Science ®Google Scholar
• Millar RP. GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2003;14:35-43
   PubMed Web of Science ®Google Scholar
• Wu HM, Wang HS, Huang HY, GnRH signaling in intrauterine tissues. Reproduction 2009;137:769-77
   PubMed Web of Science ®Google Scholar
• Cui J, Smith RG, Mount GR, Identification of Phe313 of the gonadotropin-releasing hormone (GnRH) receptor as a site critical for the binding of nonpeptide GnRH antagonists. Mol Endocrinol 2000;14:671-81
   PubMed Web of Science ®Google Scholar
• Bockaert J, Marin P, Dumuis A, Fagni L. The ‘magic tail’ of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett 2003;546:65-72
   PubMed Web of Science ®Google Scholar
• Stanislaus D, Ponder S, Ji TH, Conn PM. Gonadotropin-releasing hormone receptor couples to multiple G proteins in rat gonadotrophs and in GGH3 cells: evidence from palmitoylation and overexpression of G proteins. Biol Reprod 1998;59:579-86
   PubMed Web of Science ®Google Scholar
• Myburgh DB, Millar RP, Hapgood JP. Alanine-261 in intracellular loop III of the human gonadotropin-releasing hormone receptor is crucial for G-protein coupling and receptor internalization. Biochem J 1998;331:893-6
   PubMed Web of Science ®Google Scholar
• Yano T, Yano N, Matsumi H, Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development. Horm Res 1997;48(Suppl 3):35-41
   PubMedGoogle Scholar
• Imai A, Takagi A, Horibe S, Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 1998;83:427-31
   PubMed Web of Science ®Google Scholar
• Wang Y, Matsuo H, Kurachi O, Maruo T. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol 2002;146:447-56
   PubMed Web of Science ®Google Scholar
• Oakley AE, Clifton DK, Steiner RA. Kisspeptin signaling in the brain. Endocr Rev 2009;30:713-43
   PubMed Web of Science ®Google Scholar
• Lee JH, Miele ME, KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996;88:1731-7
   PubMed Web of Science ®Google Scholar
• de Roux N, Genin E, Carel JC, Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA 2003;100:10972-6
   PubMed Web of Science ®Google Scholar
• Seminara SB, Messager S, Chatzidaki EE, The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349:1614-27
   PubMed Web of Science ®Google Scholar
• d'Anglemont de Tassigny X, Colledge WH. The role of kisspeptin signaling in reproduction. Physiology (Bethesda) 2010;25:207-17
   PubMed Web of Science ®Google Scholar
• Gill JC, Wang O, Kakar S, Reproductive hormone-dependent and -independent contributions to developmental changes in kisspeptin in GnRH-deficient hypogonadal mice. PLoS One 2010;5:e11911
   PubMed Web of Science ®Google Scholar
• Prentice LM, Klausen C, Kalloger S, Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosisand clear cell subtype in ovarian carcinoma. BMC Med 2007;5:33
   PubMedGoogle Scholar
• Martin TA, Watkins G, Jiang WG. KiSS-1 expression in human breast cancer. Clin Exp Metastasis 2005;22:503-11
   PubMed Web of Science ®Google Scholar
• Horikoshi Y, Matsumoto H, Takatsu Y, Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. J Clin Endocrinol Metab 2003;88:914-19
   PubMed Web of Science ®Google Scholar
• Muir AI, Chamberlain L, Elshourbagy NA, AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem 2001;276:28969-75
   PubMed Web of Science ®Google Scholar
• Cuzick J. Use of LHRH-agonists as adjuvant therapy for breast cancer. Expert Opin Ther Targets 2008;12:1065-71
   PubMed Web of Science ®Google Scholar
• LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Jonat W, Blamey R, Zoladex Early Breast Cancer Research Association(ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study. Goserelin(Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39:1711-17
   PubMedGoogle Scholar
• International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003;95:1833-46
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008;14:543-52
   PubMed Web of Science ®Google Scholar
• Da Silva-Buttkus P, Marcelli G, Franks S, Inferring biological mechanisms from spatial analysis: prediction of a local inhibitor in the ovary. Proc Natl Acad Sci USA 2009;106:456-61
   PubMed Web of Science ®Google Scholar
• Petrek JA, Naughton MJ, Case LD, Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045-51
   PubMed Web of Science ®Google Scholar
• Schilsky RL, Sherins RJ, Hubbard SM, Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981;71:552-6
   PubMed Web of Science ®Google Scholar
• Anderson RA, Themmen AP, Al-Qahtani A, The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve inpremenopausal women with breast cancer. Hum Reprod 2006;21:2583-92
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465-93
   PubMed Web of Science ®Google Scholar
• Beyer DA, Amari F, Kavallaris A, Preserving fertility in patients with malignant diseases. Current strategies. Der Onkologe 2010;10; DOI 10.1007/s00761-010-1946-z
   Google Scholar
• Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-18
   PubMed Web of Science ®Google Scholar
• Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001;7:535-43
   PubMed Web of Science ®Google Scholar
• Mead G. The effects of cancer treatment on reproductive functions. Clin Med 2007;7:544-5
   PubMed Web of Science ®Google Scholar
• Gandini L, Sgro P, Lombardo F, Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod 2006;21:2882-9
   PubMed Web of Science ®Google Scholar
• Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005;83:1622-8
   PubMed Web of Science ®Google Scholar
• Rosendahl M, Andersen CY, Ernst E, Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum Reprod 2008;23:2475-83
   PubMed Web of Science ®Google Scholar
• Littley MD, Shalet SM, Beardwell CG, Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol (Oxf) 1989;31:363-73
   PubMed Web of Science ®Google Scholar
• Bath LE, Anderson RA, Critchley HO, Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia. Hum Reprod 2001;16:1838-44
   PubMed Web of Science ®Google Scholar
• Donnez J, Martinez-Madrid B, Jadoul P, Ovarian tissue cryopreservation and transplantation: a review. Hum Reprod Update 2006;12:519-35
   PubMed Web of Science ®Google Scholar
• Partridge AH, Gelber S, Peppercorn J, Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22:4174-83
   PubMed Web of Science ®Google Scholar
• Thewes B, Meiser B, Taylor A, Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005;23:5155-65
   PubMed Web of Science ®Google Scholar
• Revel A, Schenker J. Ovarian tissue banking for cancer patients: is ovarian cortex cryopreservation presently justified? Hum Reprod 2004;19:14-9
   PubMed Web of Science ®Google Scholar
• Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1:1132-4
   PubMed Web of Science ®Google Scholar
• Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72
   PubMed Web of Science ®Google Scholar
• Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004;19:1294-9
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7
   PubMed Web of Science ®Google Scholar
• Clowse ME, Behera MA, Anders CK, Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-19
   PubMed Web of Science ®Google Scholar
• Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803-11
   PubMed Web of Science ®Google Scholar
• Gerber B, Stehle H, Ricardo F, ZORO: a prospective, randomized, multicentre study to prevent chemotherapy induced ovarian failure with the GnRH agonist gosereline in young hormone insensitive breast cancer patients receiving anthracycline containing (neo) adjuvant chemotherapy (GBG 37). J Clin Oncol 2009;27:15s
   Google Scholar
• Del Mastro L, Boni L, Michelotti A, GIM Group Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group. J Clin Oncol (Meeting Abstracts) 2010;28:528
   Google Scholar
• Leonard RC, Adamson D, Anderson R, The OPTION trial of adjuvant protection by goserelin in adjuvant chemotherapy for early breast cancer. J Clin Oncol 2010;28(15 Suppl): abstract 590
   PubMed Web of Science ®Google Scholar
• Mastro LD, Levaggi A, Giraudi S, Pronzato P. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev 2010. [Epub ahead of print]
   Google Scholar
• ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update 2009;15:265-77
   PubMed Web of Science ®Google Scholar
• Chang SY, Soong YK. Unexpected pregnancies exposed to leuprolide acetate administered after the mid-luteal phase for ovarian stimulation. Hum Reprod 1995;10:204-6
   PubMed Web of Science ®Google Scholar
• Engel JB, Griesinger G, Schultze-Mosgau A, GnRH agonists and antagonists in assisted reproduction: pregnancy rate. Reprod Biomed Online 2006;13:84-7
   PubMed Web of Science ®Google Scholar
• Oliveira JB, Baruffi R, Petersen CG, Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol 2010;8:107
   PubMed Web of Science ®Google Scholar
• Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril 2010. [Epub ahead of print]
   Google Scholar
• Cantineau AE, Cohlen BJ, Heineman MJ. Ovarian stimulation protocols (anti-oestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterine insemination (IUI) in women with subfertility (Review). Cochrane Database Syst Rev 2007;(2):CD005356
   Google Scholar
• Franco JG Jr, Baruffi RL, Mauri AL, GnRH agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis. Reprod Biomed Online 2006;13:618-27
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception (Review). Cochrane Database Syst Rev 2006;(3):CD001750
   Google Scholar
• Schultze-Mosgau A, Griesinger G, Altgassen C, New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin Investig Drugs 2005;14:1085-97
   PubMed Web of Science ®Google Scholar
• Moghissi KS, Schlaff WD, Olive DL, Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998;69:1056-62
   PubMed Web of Science ®Google Scholar
• Schlaff WD. Extending the treatment boundaries: zoladex and add-back. Intern J Gynecol Obstet 1999;64(Suppl 1):S25-31
   PubMedGoogle Scholar
• Carel JC, Eugster EA, Rogol A, Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-62
   PubMed Web of Science ®Google Scholar
• Sisk CL, Zehr JL. Pubertal hormones organize the adolescent brain and behavior. Front Neuroendocrinol 2005;26:163-74
   PubMed Web of Science ®Google Scholar
• Schweppe K. Endometriose: was tun- und wann? Frauenarzt 2003;44:739-44
   Google Scholar
• Kennedy S, Bergqvist A, Chapron C, ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20:2698-704
   PubMed Web of Science ®Google Scholar
• Wheeler JM, Malinak LR. Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol 1983;146:247-25
   PubMed Web of Science ®Google Scholar
• Rotondi M, Labriola D, Rotondi M, Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol 2002;23:523-6
   PubMed Web of Science ®Google Scholar
• Cobellis L, Razzi S, Fava A, A danazol-loaded intrauterine device decreases dysmenorrheal, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril 2004;82:239-40
   PubMed Web of Science ®Google Scholar
• Razzi S, Luisi S, Calonaci F, Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril 2007;88:789-94
   PubMed Web of Science ®Google Scholar
• Surrey ES. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show? (Review). Curr Opin Obstet Gynecol 2010;22(4):283-8
   PubMed Web of Science ®Google Scholar
• Fuldeore MJ, Marx SE, Chwalisz K, Add-back therapy use and its impact on LA persistence in patients with endometriosis. Curr Med Res Opin 2010;26:729-36
   PubMed Web of Science ®Google Scholar
• Laufer MR. Current approaches to optimizing the treatment of endometriosis in adolescents. Gynecol Obstet Invest 2008;66(Suppl 1):19-27
   PubMedGoogle Scholar
• Perez-Campos EF. Ethinylestradiol/dienogest in oral contraception. Drugs 2010;70:681-9
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Vigano P, Endometriosis: current therapies and new pharmacological developments. Drugs 2009;69:649-75
   PubMed Web of Science ®Google Scholar
• Coddington CC, Grow DR, Ahmed MS, Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial. Fertil Steril 2009;91:1909-13
   PubMed Web of Science ®Google Scholar
• Hurst BS, Matthews ML, Marshburn PB. Laparoscopic myomectomy for symptomatic uterine myomas. Fertil Steril 2005;83:1-23
   PubMed Web of Science ®Google Scholar
• Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001;(2):CD000547
   Google Scholar
• Compston JE, Yamaguchi K, Croucher PI, The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995;16:261-7
   PubMed Web of Science ®Google Scholar
• West CP, Lumsden MA, Hillier H, Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids. Hum Reprod 1992;7:328-32
   PubMed Web of Science ®Google Scholar
• Morris EP, Rymer J, Robinson J, Fogelman I. Efficacy of tibolone as ‘add-back therapy’ in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids. Fertil Steril 2008;89:421-8
   PubMed Web of Science ®Google Scholar
• Mizutani T, Sugihara A, Honma H, Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy. Gynecol Endocrinol 2005;20:80-3
   PubMed Web of Science ®Google Scholar
• National Vital Statistics Report, Available from: http://www.cdc.gov/nchs/products/nvsr.htm [Last accessed 18th october 2010]
   Google Scholar
• Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging 2009;4:259-67
   PubMed Web of Science ®Google Scholar
• Deeks ED. Histrelin: in advanced prostate cancer. Drugs 2010;70:623-30
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Manola J, Loffredo M, 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-7
   PubMed Web of Science ®Google Scholar
• Informa-Pipeline, Available from: (http://informa-pipeline.citeline.com) [Last accessed 18 October 2010]
   Google Scholar
• Citeline, Available from: (http://informa.citeline.com) [Last accessed 18 October 2010]
   Google Scholar
• Chabre O, Conklin BR, Brandon S, Coupling of the alpha 2A-adrenergic receptor to multiple G-proteins. A simple approach for estimating receptor-G-protein coupling efficiency in a transient expression system. J Biol Chem 1994;269:5730-4
   PubMed Web of Science ®Google Scholar
• Emons G, Kaufmann M, Gorchev G, Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 2010;119:457-61
   PubMed Web of Science ®Google Scholar
• Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis (PubMed PMID: 20684954). Fertil Steril 2010. [Epub ahead of print]
   Google Scholar